Apolipoprotein(a) Size Heterogeneity Is Related to Variable Number of Repeat Sequences in Its mRNA

This 1990 biochemistry paper established the molecular basis of apolipoprotein(a)‘s remarkable size heterogeneity — the observation that apo(a) varies dramatically in molecular weight among individuals, an observation that had been puzzling since Lp(a) was first characterized.

By correlating mRNA transcript sizes with protein masses across a range of samples, the investigators showed that apo(a) isoform variation arises from variable numbers of tandemly repeated kringle IV-encoding sequences in the LPA gene. Larger mRNA transcripts encode larger proteins; the heterogeneity is genetic, not post-translational. Crucially, the study also confirmed the inverse relationship between isoform size and plasma Lp(a) concentration — a consequence of differential secretion and clearance by the liver.

This foundational molecular biology has direct clinical consequences. Because larger apo(a) isoforms produce lower Lp(a) levels and smaller isoforms produce higher levels, kringle IV repeat number is a primary genetic determinant of cardiovascular risk. It also explains why immunoassays calibrated against the repeating region can be systematically biased — overestimating Lp(a) in individuals with many repeats, underestimating in those with few.

We rate the evidence strong. Seminal molecular biology establishing the genetic architecture of Lp(a) variation — foundational to all subsequent work on Lp(a) measurement, risk stratification, and therapeutic targeting.